Principles of cancer chemotherapy and its clinical evaluation

4,770 views
4,598 views

Published on

0 Comments
21 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
4,770
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
497
Comments
0
Likes
21
Embeds 0
No embeds

No notes for slide

Principles of cancer chemotherapy and its clinical evaluation

  1. 1. Presenter: Dr. Jyotiman Nath
  2. 2. The term “Chemotherapy” was coined by Paul Ehrlich in early 20th century – ‘magic bullets’ in the treatment of bacterial infections Sidney Farber – father of ‘modern chemotherapy’
  3. 3. The origin of cancer chemotherapy..... WW (I) exposure of military to mustard gas led to the observation that alkylating agents caused marrow and lymphoid hypoplasia wich is further studied during WW(II) This observation led to the direct application of such agents to patients with Hodgkin’s disease and lymphocytic lymphomas at Yale Cancer Center in 1943 Luis Goodman and Alfred Gillmen demonstrated it for the first time.
  4. 4. 1948, Sydney Farber successfully used Antifolates to induce remission in children with ALL. 1955, National chemotherapy program begins at National cancer institute, a systematic programme for drug screening. 1958, Roy Hertz and Min Chiu Li demonstrated Methotrexate as a single best agent for choriocarcinoma, the first solid tumour that can be cured by chemotherapy. 1959, FDA approved the alkylating agent, Cyclophosphamide
  5. 5. 1965, The era of combination chemotherapy begins. # POMP(Methotrexate,Vincristine,6MP,Prednisolone) regimen was able to induce long term remission in children with ALL # MOPP(Nitrogen Mustard,Vincristine,Procarbazine,Prednisolone) regimen successfully cured HL and NHL used by Vincent DeVita and collegues in 1970 Currently, nearly all successful cancer chemotherapy regimens use this paradigm of multiple drugs given simultaneously, called combination chemotherapy or polychemotherapy.
  6. 6. The concept adjuvent Chemotherapy came out in 1972 when Emil Frei and collegues demonstrated chemotherapy given after surgical removal of osteosarcoma improves the cure rate. In 1992 FDA approved Paclitaxal which become the blockbuster of Oncology drugs in present scenario 2004, FDA approved Bevacizumab, the first clinically proven antiangiogenic agent for colon cancer.
  7. 7. • Neoadjuvant chemotherapy (primary or induction): given before definitive surgical therapy (in the context of locally extensive disease with a risk of distant micrometastatic disease) • Adjuvant chemotherapy: used to treat tumors with high risk of recurrence after initial local therapy (surgery and RT) has removed all evidence of disease Modalities of Cancer Chemotherapy
  8. 8. • Multimodality therapy: chemotherapy and/or radiation therapy after a tumor has been incompletely removed Concurrent Chemoradiation Chemotherapy and Hormonal therapy Biochemotherapy (Chemotherapy and Immunotherapy) Chemotherapy and Targeted therapy • Palliative chemotherapy Zoledronic acid for skeletal metastasis
  9. 9. Presently used in 4 clinical setting.... Primary induction treatment for advance disease or cancers for which no other effective treatment available As primary or neoadjuvant treatment for patients with localized disease for which local forms of therapy is ineffective Adjuvant treatment for early stage disease following local forms of treatment Direct instillation into tumour site
  10. 10.  Conventional chemotherapy targets have been the cell cycle, microtubules and DNA  Rationale for combination chemotherapy •Different drugs exert their effect through different mechanisms and at different stages of the cell cycle, thus maximize cell kill •Decease the chance of drug resistance Principles........
  11. 11. For classical chemotherapy to be effective, cell proliferation is required. Indolent (slowly growing) cancers are typically resistant. It is better to treat micrometastatic disease Maximum Tolerated Dose - this may not equate to the Maximum Therapeutic Dose
  12. 12. The only principle regarding dosage is that, dose must be adjusted to the individual patient, and that nothing can or will supersede clinical experience, and careful study, combined with good judgement.
  13. 13. PRINCIPLES FOR COMBINATION CHEMOTHERAPEUTIC REGIMENS....  All drugs must have single-agent activity  Drugs should have no overlapping toxicity  Drugs should have different mechanisms of action  Drugs should have different mechanisms or patterns of resistance  Drugs should be given in optimum dose and schedule to optimize dose intensity/dose density  Drugs should be individually titrated in individual patients to end-organ toxicity to optimize adherence to schedule
  14. 14. Primary chemotherapy: cancers for which chemo is primary treatment modality Acute Leukemia NHL HL Germ cell tumour Primary CNS lymphoma Ovarian Carcinoma Small cell lung CA Wilms tumour Embryonal rhabdomyosarcoma
  15. 15. Neoadjuvant Chemotherapy: Cancers for which Neoadjuvant chemo is usefull for locally advanced disease........... Anal Cancer Bladder Cancer Breast Cancer Cervical Cancer Gastroesophageal CA Non Small Cell lung CA Head and Neck CA Ovarian CA Osteogenic Sarcoma Rectal CA Soft tissu Sarcoma
  16. 16. Chemosensitivity of tumors ► high ALL Hodgkin’s disease NHL testicular cancer SCLC Wilms’ tumor  medium  ovarian cancer  breast cancer  osteosarcoma  head & neck cancer  multiple myeloma  bladder cancer  colorectal cancer  low  NSCLC  cervical cancer  endometrial cancer  adult soft tissue sarcoma  malignant melanoma  liver cancer  pancreatic cancer
  17. 17. Phases of cell cycle G1 - primary growth phase S – synthesis; DNA replicated G2 - secondary growth phase collectively these 3 stages are called interphase M - mitosis C - cytokinesis
  18. 18. Cell cycle
  19. 19. G0 phase (resting stage): The cell has not yet started to divide. Depending on the type of cell, G0 can last from a few hours to a few years. When the cell gets a signal to reproduce, it moves into the G1 phase: G1 phase During this phase, the cell starts making more proteins and growing larger, so the new cells will be of normal size. This phase lasts about 18 to 30 hours.
  20. 20. S phase: In the S phase, the chromosomes containing the genetic code (DNA) are copied so that both of the new cells formed will have matching strands of DNA. It lasts about 18 to 20 hours. G2 phase: The cell checks the DNA and gets ready to start splitting into 2 cells. This phase lasts from 2 to 10 hours. M phase (mitosis): In this phase, which lasts only 30 to 60 minutes, the cell actually splits into 2 new cells
  21. 21. 22 Daughter Cells DNA Copied Cells Mature Cells prepare for Division Cell Divides into Identical cells
  22. 22. Control of cell cycle- by special proteins and enzymes that act as switches G1 checkpoint- stop, pause or go into S phase some cells stop permanently G2 checkpoint- will cell divide? M checkpoint- formation of new cells
  23. 23. G1 checkpoints Rb prevents cell moving into S phase by binding to a transcription factor When Rb is phoshporylated it cannot bind so cell can move into S phase p53 prevents damaged from dividing (by inhibiting Rb pathway) Abnormalities in both genes are associated with hereditary forms of cancer
  24. 24. Action of chemotherapy drugs • Cell cycle dependent • Cell cycle independent
  25. 25. Cell cycle non-selective agents: Introduces mutations into resting DNA 1. Alkylating agents 2. DNA intercalating agents (spindle poisons - interferes with tubulin polymerization) Cell cycle selective agents: Antimetabolites of DNA synthesis
  26. 26. DNA synthesis Antimetabolites DNA DNA transcription DNA duplication Mitosis Alkylating agents Spindle poisons & Microtuble Stablizers Intercalating agents Sites of Action of Cytotoxic Agents at Cellular Level
  27. 27. Other classes of Anticancer Drugs Antitumor antibiotics Antimicrotubule agents Topoisomerase Interacting Agents Targeted therapies • Tyrosine kinase inhibitors Monoclonal antibodies Miscellaneous agents Hormonal agents
  28. 28. Alkylating agents They directly damage DNA to prevent the cancer cell from reproducing Cell cycle-specific, but not phase-specific kills a fixed percentage of cells at a given dose
  29. 29. •First chemotherapyeutic agent used in man •Prototype alkylating agent •Main toxicity comes from DNA cross linkage Nitrogen Mustard Cyclophosphamide  Mechlorethamine  Uramustine  Melphalan  Chlorambucil  Ifosfamide
  30. 30. Cyclophosphamide alkylation of DNA through the formation of reactive intermediates oral bioavailability 100% T1/2 3-10 hrs metabolism: microsomal hydroxylation hydrolysis to phosphoramide mustard and acrolein Main side effect is myelosupression Mesna is used to prevent Toxicity
  31. 31. PLATINUM ANALOGUES Cisplatin, carboplatin, oxaliplatin Cisplatin is the cornerstone drug in the modern management of head and neck cancer Carboplatin is superior to cisplatin due to less vomitting,renal and less otologic complication, BUT it is more marrow suppressive agent than Cisplatin
  32. 32. They interfere with DNA and RNA growth by substituting for the normal building blocks of RNA and DNA. These agents damage cells during the S phase Commonly used to treat...... •leukemias, •cancers of the breast •ovary, •intestinal tract, as well as other types of cancer. Antimetabolites
  33. 33. • Antifolate analogues: Methotrexate (DHFR inhibitor) Pemetrexed (multi targeted antifolate) • 5-Fluoropyrimidines: 5-FU Capecitabine S-1 (Uracil/Tegafur) Gemcitabine • Cytarabine Purine analogues: 6-mercaptopurine (6-MP) 6-thioguanine (6-TG) Fludarabine Cladribine Clofarabine Pentostatin Pyrimidine analogues: Azacitidine Hydroxyurea (analogue of urea) Antimetabolites..........
  34. 34. Antitumor Antibiotics Cell cycle non-specific agents Variety of mechanisms: prevents DNA replication, RNA production, or both Anthracyclines Anthracenediones Actinomycin D (dactinomycin) – DNA intercalator, inhibits topoisomerase II also Bleomycin – inhibits DNA synthesis, G2-phase specific Mitomycin C – functions as alkylator
  35. 35. Interfere with enzymes involved in DNA replication. These drugs work in all phases of the cell cycle Anthracyclines.... •Daunorubicin •Doxorubicin (Adriamycin) •Epirubicin •Idarubicin Anti-tumour antibiotics that are not anthracyclines include: · Actinomycin-D · Bleomycin · Mitomycin-C
  36. 36. Topoisomerase inhibitors DNA topoisomerase enzymes alters DNA topology by causing and resealing DNA breaks Topoisomerase I - relaxes supercoilded DNA Topoisomerase II - catalyzes double-stranded breaking and resealing of DNA Topoisomerase I inhibitors •Topotecan •Irinotecan Topoisomerase II inhibitors •Etoposide •Teniposide. •Mitoxantrone Epipodophylotoxins
  37. 37. Antimicrotubule (Mitotic spindle) Agents Vinca Alkaloids • Vincristine • Vinblastine • Vinorelbine • Vindesine Plant alkaloids and other compounds derived from natural products. They can stop mitosis or inhibit enzymes from making proteins needed for cell reproduction. Work during the M phase of the cell cycle but can damage cells in all phases. Taxanes •Paclitaxel •Docetaxel Estramustine (combination of estradiol and non-nitrogen mustard) Newer antitubular drug Dolastatin
  38. 38. Miscellaneous agents • Bleomycin – inhibits DNA synthesis, G2- phase specific • Asparaginase – purified from E. coli &/or Erwinia, hydrolyses asparagine, inhibits protein synthesis • Interferons – antitumor, antiproliferative, inhibits angiogenesis, regulated differentiation, NK cell activation • Interleukins – IL2 stimulates growth of activated T cells
  39. 39. Drugs that block the growth and spread of cancer by interfering with specific molecules involved in tumour growth and progression. Targeted Therapy The primary goal of targeted therapy is to fight cancer cells with more precision and potentially fewer side effects.
  40. 40. Dual (EGFR and HER2) inhibitor: Lapatinib VEGF inhibitors: Sorafenib (multi kinase inhibitor) Sunitinib (multiple TK inhibitor) Pazopanib (multi kinase inhibitor) Afitinib BCR-ABL inhibitors: Imatinib (inhibitors of bcr-abl, PDGFR, c-kit) – CML, GIST Dasatinib (multiple TK inhibitor) Nilotinib (multiple TK inhibitor) EGFR inhibitors: Gefitinib Erlotinib
  41. 41. Monoclonal antibodies • Relative selectivity for tumor tissue • Relative lack of toxicity • Various radioactive and chemotherapeutic agents can be conjugated to monoclones Drugs- Immunoconjugates - Plant toxins, Bacterial toxins Radioconjugates –Tositomumab, Ibritumumab
  42. 42. Monoclonal Antibodies in Oncology Monoclonal Antibody Construct Isotype Target Rituximab Chimeric IgG1 CD20 Cetuximab Chimeric IgG1 EGFR Panitumumab Human IgG2 EGFR Trastuzumab Humanized IgG1 HER-2 Gemtuzumab ozogamicin Humanized IgG4 CD33 Alemtuzumab Humanized IgG1 CD52 Ibritumomab tiuxetan Mouse IgG1 CD20 Bevacizumab Humanized IgG1 VEGF
  43. 43. Hormonal therapy is one of the major modalities of medical treatment for cancer Hormonal therapy It involves the manipulation of the endocrine system through exogenous administration of specific hormones, particularly steroid hormones, or drugs which inhibit the production or activity of such hormones
  44. 44. Used for several types of cancers derived from hormonally responsive tissues, including the breast, prostate, endometrium, and adrenal cortex. May also be used in the treatment of paraneoplastic syndromes. Most familiar example of hormonal therapy in oncology is the use of the selective estrogen- response modulator tamoxifen for the treatment of breast cancer, although another class of hormonal agents, aromatase inhibitors, now have an expanding role in that disease.
  45. 45. Adrenocorticosteroids: Methylprednisolone, Dexamethasone Androgens: Methyltestosterone, Fluoxymesterone Antiandrogens: Bicalutamide Flutamide Nilutamide Hormonal therapy.......... Estrogens: Diethylstilbestrol Antiestrogens: Tamoxifen, Raloxifen Fulvistrant – only antagonist effect
  46. 46. Aromatase inhibitors: (non steroidal) • Aminoglutethimide (1st generation) • Exemestane (2nd generation) • Anastrazole (3rd generation) • Letrozole (3rd generation) LHRH agonists: Leuprolide Goserelin Progestins: Megestrol Medroxyprogesterone acetate Adrenal inhibitors: Mitotane Hormonal therapy..........
  47. 47. breast cancer prostate cancer endometrial cancer renal cancer ovarin cancer cancer cachexia Hormonal therapy – indications
  48. 48. Dosage calculation in oncology • Body surface area – derived in 1916 by Du Bois – reduce the interpatient variability of drug exposure and, hence, sideeffects • AUC (carboplatin) – Dose (mg) = Target AUC (mg/mL/min) x [GFR (mL/min) + 25] • Fix dosing
  49. 49. Dosages of drugs should be adjusted for people who: · Are elderly · Have poor nutritional status · Are obese · Have already taken taking other medicines · Have already receiving radiation therapy · Have low blood cell counts · Have liver or kidney diseases
  50. 50. Chemotherapy is generally given at regular intervals called cycles. A cycle may involve a dose of one or more drugs followed by several days or weeks without treatment This gives normal cells time to recover from the drug’s side effects. Planning Chemo shedules
  51. 51. CHEMOTHERAPY TOXICITY
  52. 52. IMMEDIATE (Hours to days) •Local tissue necrosis / Extravasation •Nausea and Vomiting •Phlebitis, Skin rash •Anaphylaxis EARLY (Days to weeks) •Mucositis •Leucopenia •Thrombocytopenia •Alopecia Myelosupression
  53. 53. DELAYED (Weeks to months) • Anemia • Neurotoxicity • Pulmonary fibrosis • Nephrotoxicity • Cardiotoxicity • Hepatotoxicity LONG TERM(Over Years) • Sterility • Second malignancy - Leukemias & MDS
  54. 54. EXTRAVASATION • Some of the cytotoxic drugs are vesicants and if any leakage into the tissue occurs will cause severe ulceration and necrosis.
  55. 55. EXTRAVASATION BASIC GUIDELINES • Doubtful venepuncture • High index of suspicion • Early detection and management
  56. 56. Chemo induced Nosea and Vommiting Anticipatory Acute Delayed Chemo 16 - 24 hoursAnticipatory (24 hrs before chemotherapy) - Psychological Mechanism -Antiemetics ineffective - Behavioural therapy helpfull Acute onset (day 1) – Serotonin dependent mechanisms (peripheral) Delayed onset (day 2-5) – substance P dependent mechanisms (central)
  57. 57. Visceral Stimuli Chemoreceptor trigger zone Vestibilar input Dopamine and serotonin released Dopamine and serotonin released Histamin and acetylcholine released Medullary vommiting center stimulated Nousea and vommiting Proposed Pathways for CINV
  58. 58. Increased afferent input to the chemoreceptor trigger zone and vomiting center Chemotherapy Cell damage Higher CNS centers Release of neuroactive agentsActivation of vagus and splanchnic nerves Small intestine Chemoreceptor trigger zone Medulla oblongata Vomiting center
  59. 59. Emetogenic Risk of different drugs High risk(>90%) •CISPLATIN •CARMUSTINE •CYCLOPHOSPHAMIDE (>1.5 gm/m2) •STREPTOZOCIN •DOCARBAZINE •MECHLORETHAMINE Moderate risk(30-90%) •CARBOPLATIN •CYCLOPHOSPHAMIDE (< 1.5 gm/m2) •DOXORUBICIN •DANORUBICIN •IFOSFAMIDE •IRINOTECAN •OXALIPLATIN
  60. 60. Antiemetics 5-HT3 Antagonists Ondensetron Palonosetron Granisetron Ramosetron Aprepitant Approved in the US in 2003 MOA selective, high affinity antagonist of human substance P at neurokinin 1 (NK1) receptors interferes with the substance P pathway that produces N/V
  61. 61. Aprepitant Administration *Given for three days as part of a regimen that includes a 5-HT3 antagonist and a corticosteroid *Recommended dose 125 mg po 1 hour prior to chemotherapy 80 mg daily in the morning on days 2 and 3 *Supplied in 125- and 80-mg capsules
  62. 62. MUCOSITIS Alkylating Agents Busulfan Cyclophosphamide Procarbazine Anthracyclines Daunorubicin Doxorubicin Epirubicin Antibiotics Actinomycin Bleomycin Mitomycin Antimetabolites Cytosine Arabinoside 5-Flurouracil Hydroxyurea Methotrexate 6-Mercaptopure Taxanes Docetaxel Paclitaxel Vinca Alkaloids Vinblastine Vincristine Vinorelbine
  63. 63. MUCOSITIS MANAGEMENT PROPHYLAXIS : Maintain oral hygiene Chlorhexedine oral rinse TREATMENT : Clotrimazole Xylocaine viscous Fluconazole Acyclovir Palifermin
  64. 64. ALOPECIA * Psychologically distressing - Negative body image, Altered interpersonal relations * Rejection of curative treatment * Starts 1-2 weeks after initiation of therapy - maximum at 2 months after initiation of therapy DRUGS : Doxorubicin, Cyclophosphamide, Nitrosoureas PREVENTION: Prevent drug circulation to hair follicle 1. Scalp tourniquet 2. Scalp hypothermia (ice turban)
  65. 65. Hand foot syndrome First described in 1984 at the New England, Deaconess Hospital during 5-fluorouracil (5- FU) continuous infusion.
  66. 66. Hand-Foot syndrome….. • Common in high dose therapy, prolonged infusion, liposomal forms • Management – Stop dosing – Topical wound care & cold cream base – Pain management – Steroid creams – Pyridoxine – Avoid heat and pressure Agents Capecitabine Cytarabine Docetaxel Daunorubicin Doxorubicin 5-FU (infusion) MTX
  67. 67. DIARRHEA... Cisplatin,Dactinomycin, Docetaxel , Irinotecan capecitabine,Erlotinib,Gefitinib,Imatinib,Bortezomib
  68. 68. Organ toxicity • Nephrotoxicity • Cardiotoxicity • Hepatotoxicity • Pulmonary toxicity • CNS toxicity • PNS toxicity
  69. 69. Nephrotoxicity
  70. 70.  Patients must be hydrated before, during, and post drug administration.  Usual approach is to give at least 1 liter before and 1 liter post drug treatment of 0.9% sodium chloride with 20 mEq of KCl and 4 cc MgS04  With higher doses of drug, more aggressive hydration should be considered with at least 2 liters of fluid administered before drug  In this setting, urine output should be greater than 100 cc/hr.  Furosemide diuresis may be used after every 2 liters of fluid
  71. 71. HEPATOTOXICITY HIGH POTENTIAL LOW POTENTIAL Asparaginase Hydroxyurea Cytarabine Mercaptopurine Interferon Pentostain Methotrexate Vincristine IRREVERSIBLE Azathioprine Busulphan Carmustine Cytarabine Methotrexate Mitomycin
  72. 72. PULMONARY TOXICITY • Early-Onset Chemotherapy-Induced Lung Injury Inflammatory Interstitial Pneumonitis Pulmonary Edema [Cytarabine, all-trans- retinoic acid, interleukin-2, and bleomycin ] Bronchospasm Pleural Effusions • Late-Onset Chemotherapy-Induced Lung Injury pulmonary fibrosis. [bleomycin, busulfan, carmustine (BCNU), and mitomycin ]
  73. 73. Peripheral Neuropathy • Platinum compounds • Vinca alkaloides • Taxenes • Bortezomib • Thalidomide Cisplatin: Significant peripheral neurotoxicity Carboplatin: Carboplatin is less neurotoxic More importantly, when used in combination with paclitaxel Oxaliplatin: Acute, transient neurotoxicity
  74. 74. CNS TOXICITY • CISPLATIN: posterior leucoencephalopahty, seizures • CARBOPLATIN: thrombotic microangiopathy, optic neuropathy, seizures • 5- FU: acute cerebellar syndrome • BUSULPHAN: seizures • FLUDARABINE: delayed progressive encephalopathy • CYCLOPHOSPHAMIDE: reversible visual blurring , dizziness • DACARBAZINE: mild encephalopathy • RETINOIDS: benign intracranial hypertension
  75. 75. DELAYED EFFECCTS
  76. 76. Sterility in Men • Procarbazine most toxic • Cyclophosphamide [ 9 gm ] generally reversible • Chlorambucil [ 400 mg ] • Methotrexate • Vincristine or vinblastine • Doxorubicin • MOPP-like regimens infertility is universal by the third cycle • Only 5% to 15% ever regain effective spermatogenesis
  77. 77. Teratogenic effects • Both men and women should be strongly counseled to avoid pregnancy during active cancer treatment, when the risks of both teratogenesis and mutagenesis are highest • 5- fluorouracil, cyclophosphamide, busulfan, a nd chlorambucil anthracyclines . Cis-retinoic acid thalidomide
  78. 78. Tumor Lysis Syndrome • Large numbers of tumor cells are destroyed rapidly, resulting in intracellular contents being released into the bloodstream faster than the body can eliminate them. • Hyperkalemia is a common finding • Collaborative management includes: – Prevention – Hydration – Drug therapy (Allopurinol)
  79. 79. Drug Resistance • The main obstacle to the clinical efficacy of chemotherapy is the development of drug resistance. • Complex and multifactorial, but main causes of drug resistance are probably now understood • Inadequacy of tumor vasculature, leading to poor exposure to chemotherapeutic agents
  80. 80. Clinical Endpoints in Evaluating Response to Chemotherapy • Complete Response (CR) – Relapse-free survival after stopping treatment • Partial Response (PR) – At least a 50% reduction in measurable tumor mass • Progressive Disease (PD) – > 25% increase in one or more lesions • Stable Disease (SD) – Neither PR nor PD (no changes)
  81. 81. • MRI is commonly used to see the response after chemotherapy in solid malignancy • MRI does not always reflect tumour response after chemotherapy. Therefore, it is necessary to explore additional parameters to more accurately evaluate tumour response for the subsequent clinical determination about radiotherapy or radical surgery • In such cases PET Scan Plays a important role in clinical evaluation: 18FDG- PET
  82. 82. Monitoring of serial biomarker for evaluating response in certain cancers like *CA 125 for Ovarian Carcinoma *PSA for Prostate CA *hCG and AFP for Testicular CA CT based Tumour density assesment gained some support in evaluating treatment response in cases of GIST
  83. 83. Besides all these…….. •Routine clinical evaluation for known side effects of specific dugs •Routine check up of LFT,RFT, Serum Electrolytes etc. are of paramount important during the course of Chemotherapy treatment
  84. 84. It is easy to kill cancer cells, but the challenge is keeping the patient alive with less morbidity at the same time…..!
  85. 85. Thanks

×